Wel there's this in regard to changes in FDA requirements for contrast agents.
"Given the importance of the contrast agent for successful deployment of the Optiscan devices, coupled with the regulatory changes, the Company has also been exploring options in relation to the supply and manufacture of the drug component of the combination (device/drug) suite of products. Optiscan has been Optiscan Imaging Ltd in discussions with drug manufacturers to find appropriate pathways to resolve the changes made by the FDA in relation to the regulation of fluorescein.
The Company expects to finalise its discussions with the FDA, allowing a clearly defined path to market, for both the InVueTM and InVivage® favouring a surgical use case, which fully accommodates the FDA’s feedback and the recent US legislative changes relating to contrast agents."
- Forums
- ASX - By Stock
- Ann: OIL June 2024 Quarterly Report and Appendix 4C
Wel there's this in regard to changes in FDA requirements for...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OIL (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $133.6M |
Open | High | Low | Value | Volume |
16.5¢ | 16.5¢ | 16.0¢ | $12.29K | 75.08K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17061 | 16.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.5¢ | 29875 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17061 | 0.160 |
3 | 227800 | 0.155 |
6 | 61284 | 0.150 |
2 | 49561 | 0.145 |
4 | 72133 | 0.140 |
Price($) | Vol. | No. |
---|---|---|
0.165 | 29875 | 2 |
0.170 | 7000 | 1 |
0.175 | 25000 | 2 |
0.180 | 3003 | 1 |
0.190 | 35833 | 2 |
Last trade - 15.34pm 10/10/2024 (20 minute delay) ? |
Featured News
OIL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online